Connect Biopharma Holdings (CNTB) Common Equity (2020 - 2026)
Connect Biopharma Holdings (CNTB) posted Common Equity of $42.6 million for Q1 2026, up 1.53% sequentially from $42.0 million in Q4 2025, and down 48.58% YoY from $82.9 million in Q1 2025.
Connect Biopharma Holdings (CNTB) Common Equity (2020 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Common Equity for 7 years, with the latest figure at $42.6 million in Q1 2026.
- Quarterly Common Equity fell 48.58% year-over-year to $42.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.6 million (down 48.58% YoY) and the FY2025 annual result came in at $42.0 million, down 54.45% from the prior year.
- Common Equity rose to $42.6 million in Q1 2026 per CNTB's latest filing, from $42.0 million in the prior quarter.
- Over five years, Common Equity peaked at $213.0 million in Q2 2022 and troughed at $42.0 million in Q4 2025.
- A 5-year average of $99.2 million and a median of $93.9 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity decreased 9.19% in 2024, then sank 54.45% in 2025.
- Over 5 years, Common Equity stood at $154.2 million in 2022, then plunged by 34.19% to $101.5 million in 2023, then fell by 9.19% to $92.2 million in 2024, then plunged by 54.45% to $42.0 million in 2025, then increased by 1.53% to $42.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $42.6 million, $42.0 million, and $55.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Connect Biopharma Holdings | 144.32 Mn | 144.32 Mn | - | 26.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.86 Mn |
| Mar 31, 2026 | 42.62 Mn |
| Dec 31, 2025 | 41.98 Mn |
| Sep 30, 2025 | 55.37 Mn |
| Jun 30, 2025 | 71.34 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | 92.17 Mn |
| Sep 30, 2024 | 100.65 Mn |
| Jun 30, 2024 | 110.93 Mn |
| Mar 31, 2024 | 93.90 Mn |
| Dec 31, 2023 | 101.50 Mn |
| Jun 30, 2023 | 128.67 Mn |
| Dec 31, 2022 | 154.22 Mn |
| Jun 30, 2022 | 212.99 Mn |
| Dec 31, 2021 | 271.50 Mn |
| Dec 31, 2020 | -154.66 Mn |